Financial Performance - The company reported unaudited revenue of HKD 10,467,000 for the three months ended June 30, 2022, a decrease of 23.8% compared to HKD 13,646,000 for the same period in 2021[5]. - The loss before tax for the period was HKD 799,000, compared to a profit of HKD 1,571,000 in the previous year[5]. - The company experienced a significant decline in revenue from treatment services, which amounted to HKD 8,165,000, down 25.4% from HKD 10,949,000 in the prior year[14]. - Revenue from prescription and dispensing services decreased to HKD 2,077,000, a decline of 11.7% from HKD 2,354,000 in the same quarter of 2021[14]. - The company reported a basic and diluted loss per share of HKD 0.20 for the quarter, compared to earnings of HKD 0.38 per share in the previous year[5]. - The total comprehensive loss attributable to owners of the company was HKD 792,000, compared to a comprehensive income of HKD 1,529,000 in the same period last year[5]. - For the three months ended June 30, 2022, the company's revenue decreased by HKD 3.1 million or 22.8% to HKD 10.5 million compared to the same period in 2021[34]. - The company recorded a loss attributable to owners of HKD 0.8 million for the three months ended June 30, 2022, compared to a profit of HKD 1.5 million for the same period in 2021[36]. - The group's revenue decreased by HKD 3.1 million or 22.8% from HKD 13.6 million for the three months ended June 30, 2021, to HKD 10.5 million for the three months ended June 30, 2022, primarily due to the negative impact of the fifth wave of the COVID-19 pandemic and intense market competition[39]. - Other income, gains, and losses netted a loss of HKD 0.043 million for the three months ended June 30, 2022, a decrease of HKD 0.4 million or 66.7% from a net income of HKD 0.3 million for the same period in 2021, mainly due to unrealized exchange losses and the net impact of government subsidies[40]. Assets and Liabilities - The company’s total assets as of June 30, 2022, were HKD 16,657,000, a decrease from HKD 23,445,000 as of June 30, 2021[7]. - The cost of used inventory for the three months ended June 30, 2022, was HKD 2.0 million, representing 18.7% of the revenue, compared to HKD 2.2 million or 16.3% of the revenue for the same period in 2021[41]. - Employee costs decreased by HKD 0.7 million or 12.5% from HKD 5.6 million for the three months ended June 30, 2021, to HKD 4.9 million for the same period in 2022, primarily due to reduced salaries and bonuses linked to decreased revenue[42]. - Other expenses decreased by HKD 0.3 million or 14.3% from HKD 2.1 million for the three months ended June 30, 2021, to HKD 1.8 million for the same period in 2022, primarily due to reduced revenue[46]. Business Strategy and Operations - The company is focused on providing medical consultation services, prescription and dispensing services, and treatment services as its main business segments[12]. - The company has implemented measures to enhance online consultation services and e-commerce platforms for its skincare products[34]. - The board believes that introducing new services and products is one of the key drivers for business growth and maintaining competitiveness in the industry[37]. - The group will continue to adopt a cautious approach to business strategy due to uncertainties and challenges posed by the COVID-19 pandemic[37]. - The company aims to leverage its solid customer base and good reputation in the industry to provide high-quality medical skin care services and products, thereby solidifying its market position and seeking new business opportunities[37]. Governance and Compliance - The board of directors confirmed that the financial statements are accurate and complete, with no misleading or fraudulent elements[3]. - The company adopted the corporate governance code as per GEM Listing Rules Appendix 15 and has complied with it for the three months ending June 30, 2022[59]. - The audit committee, consisting of three independent non-executive directors, reviewed the financial statements for the three months ending June 30, 2022, ensuring compliance with applicable accounting standards and GEM Listing Rules[66]. - The roles of the chairman and CEO are held by the same individual, Dr. Jiang, to enhance business strategy implementation and operational efficiency[61]. - The board of directors is committed to maintaining a positive relationship between executive and non-executive directors, ensuring collective responsibility for business strategy[61]. - The company encourages active participation from all directors in board affairs to align with the best interests of the company[61]. - The company has not reported any violations of the securities trading rules for directors during the three months ending June 30, 2022[62]. Dividends and Share Options - The company did not declare an interim dividend for the three months ended June 30, 2022, compared to a special dividend of HKD 9,918,000 declared in 2021[26][25]. - As of June 30, 2022, there were 4,000,000 unexercised share options outstanding, unchanged from the previous year[65]. - The company has established a share option scheme to reward eligible individuals for their contributions, in line with GEM Listing Rules[65]. Market Conditions - The company faced significant competition in the market and was impacted by strict social distancing measures due to the fifth wave of COVID-19 in Hong Kong[34]. - The company received government subsidies of HKD 576,000 under the "Employment Support Scheme" to alleviate the impact of the COVID-19 pandemic[20][21]. - There were no significant events occurring after the reporting period[30]. - The depreciation of right-of-use assets remained stable at HKD 1.8 million for the three months ended June 30, 2022, compared to HKD 1.9 million for the same period in 2021[44]. - The company has not purchased, sold, or redeemed any of its listed securities during the reporting period[63]. - No securities transactions were conducted by the company or its subsidiaries during the three months ending June 30, 2022[63].
密迪斯肌(08307) - 2023 Q1 - 季度财报